Genomic variants associated with age at diagnosis of childhood-onset type 1 diabetes.
Pierre BougnèresSophie Le FurYoichiro KamataniThanh-Nga MaiMarie-Pierre BelotKevin Pergenull nullXiaoJian ShaoMark LathropAlain-Jacques ValleronPublished in: Journal of human genetics (2024)
Age at diagnosis (AAD) of Type 1 diabetes (T1D) is determined by the age at onset of the autoimmune attack and by the rate of beta cell destruction that follows. Twin studies found that T1D AAD is strongly influenced by genetics, notably in young children. In young UK, Finnish, Sardinian patients AAD-associated genomic variants were previously identified, which may vary across populations and with time. In 1956 children of European ancestry born in mainland France in 1980-2008 who declared T1D before 15 years, we tested 94 T1D-associated SNPs for their association with AAD using nonparametric Kruskal-Wallis test. While high-risk HLA genotypes were not found to be associated with AAD, fourteen SNPs located in 12 non-HLA loci showed a strong association (2.9 × 10 -12 < P < 1.4 × 10 -3 after FDR correction). Four of these loci have been associated with AAD in previous cohorts (GSDMB, IL2, TNFAIP3, IL1), supporting a partially shared genetic influence on AAD of T1D in the studied European populations. In contrast, the association of 8 new loci CLEC16A, TYK2, ERBB3, CCR7, FCRL3, DNAH2, FGF3/4, and HPSE2 with AAD is novel. The 12 protein-coding genes located within these loci are involved in major immune pathways or in predisposition to other autoimmune diseases, which suggests a prominent role for these genes in the early immune mechanisms of beta cell destruction.
Keyphrases
- genome wide
- copy number
- dna methylation
- type diabetes
- genome wide association
- genome wide association study
- cardiovascular disease
- cell therapy
- single cell
- multiple sclerosis
- newly diagnosed
- stem cells
- young adults
- adipose tissue
- tyrosine kinase
- computed tomography
- skeletal muscle
- dendritic cells
- transcription factor
- middle aged
- patient reported outcomes
- glycemic control
- gestational age
- contrast enhanced
- early life